BACKGROUND Although cardiac allograft vasculopathy (CAV) is typically characterized by diffuse coronary intimal
All-cause death or re-transplantation Acute cellular rejection (%) (especially insulin) at 1 year ( Table 3) . Although severe rejection with hemodynamic compromise tended to be more frequent in patients with ASP progression compared with those without, occurrence of AMR (grade 2 or higher) or development of de novo DSA during the first year was not significantly different between the 2 groups. Among several clinical differences, the occurrence of acute cellular rejection during the first year was strongly associated with 1-year ASP progression (odds ratio: 11.99; 95% CI: Values are median (interquartile range), %, or mean AE SD. *Oral antidiabetic drugs and/or insulin. †1 or more episodes of grade $2R or 2 during the first year post-transplant. ‡Severe rejection with hemodynamic compromise, defined as a decrease in relative LVEF >25%. §Primarily used during the first year post-transplant. Tables 1 and 2 . Table 4) . This association was preserved in a sensitivity analysis restricted to cardiac death and retransplantation (n ¼ 13) ( Table 5) .
Abbreviations as in
Acute cellular rejection during the first year was also associated with all-cause death or retransplantation but not with cardiac death or retransplantation (Tables 4 and 5 ).
DISCUSSION
The main findings of this study are: 1) 10.5% of patients experienced ASP progression during the first year post-transplant; 2) ASP progression at 1 year was an independent predictor of long-term mortality or retransplantation; and 3) ASP progression at 1 year was also associated with the occurrence of significant acute cellular rejection during the first year posttransplant. However, early coronary intimal thickening or arterial remodeling alone did not predict long-term mortality or retransplantation in multivariate analyses. To the best of our knowledge, this was the first study to suggest the potential clinical utility of serial IVUS assessment of coronary plaque instability in CAV to predict long-term outcomes after heart transplantation.
ASP PROGRESSION IN CAV. Our findings suggested that importantly, ASP can be used to identify highrisk patients after heart transplantation. In native coronary atherosclerosis, ASP is predominantly caused by a combination of factors related to plaque instability (inflammatory plaque), such as large plaque burden, microcalcification, plaque rupture, and presence of thin-capped fibroatheroma characterized by lipid-rich plaque with macrophage infiltration and a large necrotic core (8, 17) . As in native atherosclerosis (18, 19) , these components of plaque instability can be encountered in CAV lesions as well (7, 20, 21) , and some of them (particularly increased lipid-rich, necrotic core and dense calcium) are associated with adverse clinical events in heart transplant recipients, such as recurrent acute cellular rejection, CAV progression, and need for revascularization (7, 22) . A histopathological study also demonstrated that in late after transplantation (12, 20, 31) . The present study extended these investigations by indicating that the thrombosis theory might also apply to CAV and that plaque instability could cause cardiac events regardless of significant coronary intimal thickening and/or negative vessel remodeling, suggesting that plaque instability is an important independent risk factor for CAV progression. 
